Tango Therapeutics (TNGX) investor relations material

Study background and design

• Vopimetostat is an oral, once-daily, MTAP-selective PRMT5 inhibitor evaluated in a multicenter, open-label phase I/II trial for MTAP-deleted solid tumors, including pancreatic, lung, and histology-agnostic cohorts.

• The study enrolled 179 patients, with 154 at active doses and 84 at the go-forward 250 mg QD dose; key cohorts included pancreatic (n=64), lung (n=41), and histology-agnostic (n=47).

• Over 60,000 patients per year in the U.S. have MTAP-deleted solid tumors, with pancreatic and lung cancer as key initial targets.

• The study is progressing toward a pivotal, global, randomized phase III trial in second-line MTAP-deleted pancreatic cancer, with future plans for first-line combination studies.

• Additional disclosures and data updates, including new brain-penetrant compounds and combination studies, are planned for 2026.

Efficacy and clinical results

• Vopimetostat achieved a 27% overall response rate (ORR) and 78% disease control rate (DCR) across all histologies, with a median progression-free survival (mPFS) of 6.4 months and a median follow-up of 9.4 months.

• In second-line pancreatic cancer, ORR was 25% and mPFS was 7.2 months, more than doubling historical standards.

• The histology-agnostic cohort had a 49% ORR, 89% DCR, and mPFS of 9.1 months, with activity seen across 13–16 cancer types.

• Efficacy improved with longer follow-up, and nearly 40% of patients remained on study at 9.4 months.

• Vopimetostat outperformed standard-of-care chemotherapy in both pancreatic and histology-agnostic cohorts.

Safety and tolerability

• Vopimetostat at 250 mg QD demonstrated a best-in-class safety profile, with most treatment-related adverse events being grade 1 and occurring in fewer than 10% of patients.

• No grade 4/5 drug-related events or discontinuations due to adverse events were reported; 8% required dose reduction, mainly for anemia.

• Most common adverse events included nausea (26%), anemia (20%), fatigue (19%), dysgeusia (19%), and thrombocytopenia (13%).

• The 250 mg dose was selected as optimal for efficacy and tolerability, with higher doses leading to increased bone marrow suppression.

• Safety profile supports combination with chemotherapy or targeted agents, with no overlapping toxicity observed in early combination studies.